From drought to demand: Biotech IPOs roar back with Kailera and Alamar
Strong demand for GLP-1 drugs and next-gen diagnostic testing is pulling investors back into life sciences, even as AI soaks up most venture dollars.
Original Source
Read the full article at Fortune →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.